Cargando…
Development of a potency assay for CD34(+) cell-based therapy
We have previously shown that intracardiac delivery of autologous CD34(+) cells after acute myocardial infarction (AMI) is safe and leads to long term improvement. We are now conducting a multicenter, randomized, controlled Phase I/IIb study in post-AMI to investigate the safety and efficacy of intr...
Autores principales: | Aries, Anne, Vignon, Christine, Zanetti, Céline, Goubaud, Aurélien, Cormier, Arthur, Diederichs, Anne, Lahlil, Rachid, Hénon, Philippe, Garitaonandia, Ibon |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10640600/ https://www.ncbi.nlm.nih.gov/pubmed/37952030 http://dx.doi.org/10.1038/s41598-023-47079-8 |
Ejemplares similares
-
Deciphering the Cardiovascular Potential of Human CD34(+) Stem Cells
por: Aries, Anne, et al.
Publicado: (2023) -
Industrialized GMP Production of CD34(+) Cells (ProtheraCytes®) at Clinical Scale for Treatment of Ischemic Cardiac Diseases Is Feasible and Safe
por: Hénon, Philippe, et al.
Publicado: (2022) -
Evaluation of expanded peripheral blood derived CD34+ cells for the treatment of moderate knee osteoarthritis
por: Vignon, Christine, et al.
Publicado: (2023) -
Differential Expression of the Tetraspanin CD9 in Normal and Leukemic Stem Cells
por: Lahlil, Rachid, et al.
Publicado: (2021) -
VSELs Maintain their Pluripotency and Competence to Differentiate after Enhanced Ex Vivo Expansion
por: Lahlil, Rachid, et al.
Publicado: (2018)